PCR and MLPA

PCR and MLPA

Polymerase Chain Reaction, and closely related methods such as qPCR and dPCR can provide a simple and cost-effective method of analysing DNA and RNA samples for the presence of particular variants of interest.

This device utilises fluorescently-tagged probe molecules to assess up to 800 biomarkers in parallel, with no pre-amplification required. It is particularly well suited to analysis of FFPE samples and copes well with the degraded nature of target material isolated from this source. RNA and proteins can be analysed, in some cases in parallel during the same reaction and sample quantity requirements are small.

NewGene have significant experience in creating and performing PCR assays and can advise on technique and experimental design to best suit project requirements. NewGene utilises the Roche LightCycler 480 qPCR, BioRad QX200 droplet digital PCR and other conventional end-point PCR systems.

MLPA (Multiplex Ligation-dependent Probe Amplification) is a multiplex PCR method detecting abnormal copy number variation (CNV) in genomic DNA or RNA sequences. It is able to differentiate between sequences differing in only one nucleotide. Although for most hereditary conditions, (partial) gene deletions or duplications account for less than 10 % of all disease-causing mutations, in several disorders this is up to 30%. The use of MLPA can therefore significantly increase the detection rate of many genetic disorders.

Contact us

NewGene Limited
Bioscience Building
International Centre for Life
Newcastle upon Tyne
NE1 4EP, UK

Tel: +44 (0)191 242 1923
Fax: +44 (0)191 241 8799
Email: info@newgene.org.uk

Click here for location map

Mon – Fri 08:30 to 17:00, closed Bank Holidays

An ISO 15189 accredited Medical Laboratory company

NewGene Limited | Company Number: 06735445

Technology Partners

Agilent Technologies

Agena Bioscience

Illumina

Sophia Genetics

Qiagen

Promega

Enquiry form